C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice

Journal of Virology

Volumn 87, Issue 19, 2013, Pages 10784-10791

  Denard, Jerome ^a   Marolleau, Beatrice ^a   Jenny, Christine ^a   Rao, Tata Nageswara ^b,c,d   Fehling, Hans Jörg ^b   Voit, Thomas ^e   Svinartchouk, Fedor ^a  

^a GÉNÉTHON   (France)

^b UNIVERSITY OF ULM   (Germany)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BINDING PROTEIN; C REACTIVE PROTEIN; GALECTIN 3 BINDING PROTEIN; MURINE SECRETED EMBRYONIC ALKALINE PHOSPHATASE; PARVOVIRUS VECTOR; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 1; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 6; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 8; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR 9; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; BODY FLUID; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REPORTER GENE; SEROTYPE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRAIN DIFFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84885996555     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01813-13     Document Type: Article

References (53)

1. Bartlett JS, Wilcher R, Samulski RJ. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74: 2777-2785.
2. Schuhmann NK, Pozzoli O, Sallach J, Huber A, Avitabile D, Perabo L, Rappl G, Capogrossi MC, Hallek M, Pesce M, Buning H. 2010. Gene transfer into human cord blood-derived CD34(+) cells by adenoassociated viral vectors. Exp. Hematol. 38:707-717.
3. Seiler MP, Miller AD, Zabner J, Halbert CL. 2006. Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum. Gene Ther. 17:10-19.
4. O'Donnell J, Taylor KA, Chapman MS. 2009. Adeno-associated virus-2 and its primary cellular receptor-cryo-EM structure of a heparin complex. Virology 385:434-443.
5. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
6. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. 2006. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80:9093-9103.
7. Cheng B, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SW, McGoogan KE, Aslanidi GV, Park M, Stacpoole PW, Siemann D, Liu C, Srivastava A, Ling C. 2012. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther. 19:375-384.
8. Ling C, Lu Y, Cheng B, McGoogan KE, Gee SW, Ma W, Li B, Aslanidi GV, Srivastava A. 2011. High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. J. Vis. Exp. 49:e2538. doi:10.3791/2538.
9. Ling C, Lu Y, Kalsi JK, Jayandharan GR, Li B, Ma W, Cheng B, Gee SW, McGoogan KE, Govindasamy L, Zhong L, Agbandje-McKenna M, Srivastava A. 2010. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum. Gene Ther. 21: 1741-1747.
10. Denard J, Beley C, Kotin R, Lai-Kuen R, Blot S, Leh H, Asokan A, Samulski RJ, Moullier P, Voit T, Garcia L, Svinartchouk F. 2012. Human galectin 3 binding protein interacts with recombinant adenoassociated virus type 6. J. Virol. 86:6620-6631.
11. Black S, Kushner I, Samols D. 2004. C-reactive protein. J. Biol. Chem. 279:48487-48490.
12. Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. 2011. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem. 286:6272-6279.
13. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE. 2010. Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin. Transl. Sci. 3:81-89.
14. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. 2008. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16:1073-1080.
15. Drittanti L, Jenny C, Poulard K, Samba A, Manceau P, Soria N, Vincent N, Danos O, Vega M. 2001. Optimised helper virus-free production of high-quality adeno-associated virus vectors. J. Gene Med. 3:59-71.
16. Wright JF. 2009. Transient transfection methods for clinical adenoassociated viral vector production. Hum. Gene Ther. 20:698-706.
17. Hermens WT, ter Brake O, Dijkhuizen PA, Sonnemans MA, Grimm D, Kleinschmidt JA, Verhaagen J. 1999. Purification of recombinant adenoassociated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther. 10:1885-1891.
18. Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H. 1993. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol. 5:957-964.
19. Wang M, Orsini C, Casanova D, Millan JL, Mahfoudi A, Thuillier V. 2001. MUSEAP, a novel reporter gene for the study of long-term gene expression in immunocompetent mice. Gene 279:99-108.
20. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21:704-712.
21. Arnett AL, Beutler LR, Quintana A, Allen J, Finn E, Palmiter RD, Chamberlain JS. 2013. Heparin-binding correlates with increased efficiency of AAV1-and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene Ther. 20:497-503.
22. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80:11393-11397.
23. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ. 2010. Reengineering a receptor footprint of adenoassociated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28:79-82.
24. Kotchey NM, Adachi K, Zahid M, Inagaki K, Charan R, Parker RS, Nakai H. 2011. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19:1079-1089.
25. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-9836.
26. Hauck B, Xiao W. 2003. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 77:2768-2774.
27. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75:6884-6893.
28. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K, Nakamura T, Watanabe M, Oshimi K, Daida H. 2005. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79:609-614.
29. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286:13532-13540.
30. Shen S, Bryant KD, Sun J, Brown SM, Troupes A, Pulicherla N, Asokan A. 2012. Glycan binding avidity determines the systemic fate of adenoassociated virus type 9. J. Virol. 86:10408-10417.
31. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. 2006. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12:787-789.
32. Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. 2008. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol. Ther. 16:657-664.
33. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier C. 2012. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J. Immunol. 188:6418-6424.
34. Zaiss AK, Muruve DA. 2008. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 15:808-816.
35. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, Bartlett JS, Muruve DA. 2008. Complement is an essential component of the immune response to adeno-associated virus vectors. J. Virol. 82:2727-2740.
36. Francis T, Tillett WS. 1930. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of typespecific polysaccharide. J. Exp. Med. 52:573-585.
37. Volanakis JE, Kaplan MH. 1971. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136:612-614.
38. Ohnishi S, Maeda S, Nishiguchi S, Arao T, Shimada K. 1988. Structure of the mouse C-reactive protein gene. Biochem. Biophys. Res. Commun. 156:814-822.
39. Thompson D, Pepys MB, Wood SP. 1999. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7:169-177.
40. Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, Pepys MB, Bloomer AC, Greenhough TJ. 1996. Three dimensional structure of human C-reactive protein. Nat. Struct. Biol. 3:346-354.
41. Bang R, Marnell L, Mold C, Stein MP, Clos KT, Chivington-Buck C, Clos TW. 2005. Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis. J. Biol. Chem. 280:25095-25102.
42. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. 2006. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217-1221.
43. Pepys MB, Hirschfield GM. 2003. C-reactive protein: a critical update. J. Clin. Invest. 111:1805-1812.
44. Ballou SP, Kushner I. 1992. C-reactive protein and the acute phase response. Adv. Intern. Med. 37:313-336.
45. Siboo R, Kulisek E. 1978. A fluorescent immunoassay for the quantification of C-reactive protein. J. Immunol. Methods 23:59-67.
46. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. 1995. C-reactive protein binds to Fc gamma RI in transfected COS cells. J. Immunol. 155:2185-2193.
47. Mold C, Gresham HD, Du Clos TW. 2001. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J. Immunol. 166:1200-1205.
48. Muller H, Fehr J. 1986. Binding of C-reactive protein to human polymorphonuclear leukocytes: evidence for association of binding sites with Fc receptors. J. Immunol. 136:2202-2207.
49. Stein MP, Mold C, Du Clos TW. 2000. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J. Immunol. 164:1514-1520.
50. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. 2001. Topology and structure of the C1q-binding site on C-reactive protein. J. Immunol. 166:3998-4004.
51. Gaboriaud C, Juanhuix J, Gruez A, Lacroix M, Darnault C, Pignol D, Verger D, Fontecilla-Camps JC, Arlaud GJ. 2003. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem. 278:46974-46982.
52. Devaraj S, Kumaresan PR, Jialal I. 2004. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J. Mol. Cell. Cardiol. 36:405-410.
53. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168.